The biologic drugs currently available (anti-IgE, anti-IL4Rα, anti-IL5, and anti-IL5Rα) for severe asthma are currently undergoing clinical development studies to extend their availability to patients with nasal polyposis. This evidence concerns the gene IL4R and asthma.